Neurocrine Biosciences, Inc. - Common Stock (NBIX)
120.29
+10.54 (9.60%)
NASDAQ · Last Trade: May 6th, 2:37 PM EDT
Detailed Quote
Previous Close
109.75
Open
123.00
Bid
120.01
Ask
120.56
Day's Range
116.56 - 130.46
52 Week Range
84.23 - 157.98
Volume
3,504,601
Market Cap
11.91B
PE Ratio (TTM)
36.56
EPS (TTM)
3.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,742,674
Chart
About Neurocrine Biosciences, Inc. - Common Stock (NBIX)
Neurocrine Biosciences is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine diseases. The company conducts research and creates drug therapies aimed at addressing the unmet medical needs of patients suffering from conditions such as movement disorders, psychiatric disorders, and hormonal disorders. Through a combination of scientific expertise and cutting-edge technology, Neurocrine strives to enhance patient outcomes and improve quality of life, while expanding its pipeline of therapeutic options in the field of neuroscience and endocrinology. Read More
CEO Kyle Gano highlighted record new patient starts for Ingrezza and noted positive early response to the launch of Crenessity, positioning the company for sustained growth.
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.
Discover NEUROCRINE BIOSCIENCES INC, an undervalued stock. NASDAQ:NBIX showcases solid financial health and profitability while maintaining an appealing valuation.
Based on a technical and fundamental analysis of NASDAQ:NBIX we can say: NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
NEUROCRINE BIOSCIENCES INC has a stellar value proposition. NASDAQ:NBIX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
